TCP
GILD icon

TMB Capital Partners’s Gilead Sciences GILD Stock Holding History

TMB Capital Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$236K Buy
1,868
+4
+0.2% +$527 0.07% 151
2026
Q1 		$260K Buy
1,864
+4
+0.2% +$560 0.09% 150
2025
Q4 		$228K Buy
+1,860
New +$226K 0.08% 154

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TMB Capital Partners's GILD Position: Q2 2026 in Review

TMB Capital Partners increased its Gilead Sciences (GILD) stake by 0.21% in Q2 2026, buying an estimated $527 and bringing the position to 1,868 shares worth $236K. The position accounts for 0.07% of the portfolio, ranked #151.

TMB Capital Partners first reported a position in GILD in Q4 2025 and has held it in 3 quarters since. The position peaked at $260K in Q1 2026. 2,272 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • TMB Capital Partners held 1,868 shares of Gilead Sciences worth $236K as of Q2 2026.
  • TMB Capital Partners bought 4 Gilead Sciences shares in Q2 2026, an estimated $527.
  • Gilead Sciences made up 0.07% of TMB Capital Partners's portfolio in Q2 2026, its #151 holding.
  • TMB Capital Partners first reported a position in Gilead Sciences in Q4 2025 and has held it in 3 quarters since.
  • TMB Capital Partners's Gilead Sciences position peaked at $260K in Q1 2026.
  • 2,272 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on TMB Capital Partners's 13F filing for Q2 2026, filed 24 Jul 2026.